Core Viewpoint - The company, He Yuan Bio, is navigating through a challenging period in the biopharmaceutical industry by focusing on technological barriers and production efficiency as key factors for sustainable growth [1] Group 1: Financial Performance - In the first half of 2025, He Yuan Bio reported a revenue of 119.85 million yuan, representing a year-on-year growth of 6.01% [1] - The net profit attributable to the parent company was -104.57 million yuan, a decrease in loss of 8.78 million yuan compared to the same period last year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was -104.51 million yuan, a decrease in loss of 14.90 million yuan year-on-year [1] Group 2: Business Development - The CRO business segment achieved sales revenue of 40.70 million yuan, a year-on-year increase of 3.79%, serving over 14,000 research laboratory clients [2] - The CDMO business maintained its leading position with sales revenue of 65.62 million yuan, remaining stable compared to the previous year [2] - The company assisted clients in obtaining 52 domestic and international IND approvals and undertook over 540 CDMO projects, with new orders exceeding 90 million yuan in the year [2] Group 3: Regenerative Medicine Progress - He Yuan Bio has made significant advancements in regenerative medicine, including the development of processes for stem cells and immune cells [3] - The company’s subsidiary, He Yuan He Mei, successfully registered human dermal fibroblast exosomes in the global cosmetics ingredient directory, expanding its market opportunities [3] - The company is enhancing its production capacity at its Lingang industrial base, which is now fully operational, positioning itself among the top in the international industry [3] Group 4: R&D and Technological Innovation - In the first half of 2025, He Yuan Bio invested 23.21 million yuan in R&D, accounting for 19.37% of its revenue, and filed for 10 new patents [4] - The company is leveraging AI technology to enhance research and production efficiency, developing an intelligent R&D system that integrates AI with production data [5] - The AI models developed by the company are being applied across various R&D projects, significantly improving efficiency [5] Group 5: Market Outlook - Despite the current adjustment period in the CGT CDMO industry, the long-term growth potential remains intact, with projections indicating that the global and Chinese CGT CDMO market will reach $27.45 billion and $4.48 billion by 2030, respectively [6] - The company is expected to strengthen its competitive edge through optimized capacity and order growth, combined with deep integration of technology and AI [6] - As the biopharmaceutical industry improves, He Yuan Bio is poised to accelerate its growth potential in the cell and gene therapy sector [6]